Loading
A phase 2 trial of Purinostat in peripheral T-cell lymphomas, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma is a phase 2 interventional study registered as NCT06485219 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 50 participants enrolled, started 2024-04-14 and due to reach its primary completion in 2026-06-30. Interventions recorded: 11.2 mg/m2 Purinostat Mesylate and 15 mg/m2 Purinostat Mesylate.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.